Trials / Completed
CompletedNCT00072722
Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)
Phase II Randomized Open-Label, Two-Arm Study of Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (planned)
- Sponsor
- Celgene Corporation · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase II randomized open-label, two-arm study of safety and efficacy of CC-4047 in subjects with metastatic hormone refractory prostate cancer (HRPC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-4047 |
Timeline
- Start date
- 2003-09-01
- Completion
- 2005-04-01
- First posted
- 2003-11-13
- Last updated
- 2006-12-19
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00072722. Inclusion in this directory is not an endorsement.